LEXICON PHARMACEUTICALS, INC. Costs and Expenses
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Costs and Expenses of $27.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-06-30 was $27.23M, a 8.36% increase year-over-year.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2026-03-31 was $22.10M, a 17.98% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-12-31 was $20.27M, a 65.81% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for the quarter ending 2025-09-30 was $26.37M, a 59.71% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for fiscal 2025 was $98.71M, a 56.74% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for fiscal 2024 was $228.20M, a 31.94% increase from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for fiscal 2023 was $172.95M, a 71.41% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. costs and expenses for fiscal 2022 was $100.90M, a 15.46% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $27.23M 10-Q · filed 2026-08-06 | $49.33M 10-Q · filed 2026-08-06 | $69.60M derived: sum of 3 quarters · filed 2026-08-06 | $95.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $22.10M 10-Q · filed 2026-05-07 | $42.37M derived: sum of 2 quarters · filed 2026-05-07 | $68.74M derived: sum of 3 quarters · filed 2026-05-07 | $93.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $46.64M derived: sum of 2 quarters · filed 2026-03-05 | $71.77M derived: sum of 3 quarters · filed 2026-08-06 | $98.71M 10-K · filed 2026-03-05 |
| 2025-09-30 | $26.37M 10-Q · filed 2025-11-06 | $51.50M derived: sum of 2 quarters · filed 2026-08-06 | $78.44M 10-Q · filed 2025-11-06 | $137.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $25.13M 10-Q · filed 2026-08-06 | $52.07M 10-Q · filed 2026-08-06 | $111.36M derived: sum of 3 quarters · filed 2026-08-06 | $176.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $26.94M 10-Q · filed 2026-05-07 | $86.23M derived: sum of 2 quarters · filed 2026-05-07 | $151.68M derived: sum of 3 quarters · filed 2026-05-07 | $208.68M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $59.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $124.73M derived: sum of 2 quarters · filed 2026-03-05 | $181.74M derived: sum of 3 quarters · filed 2026-03-05 | $228.20M 10-K · filed 2026-03-05 |
| 2024-09-30 | $65.44M 10-Q · filed 2025-11-06 | $122.44M derived: sum of 2 quarters · filed 2025-11-06 | $168.91M 10-Q · filed 2025-11-06 | $216.35M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $57.00M 10-Q · filed 2025-08-06 | $103.46M 10-Q · filed 2025-08-06 | $150.90M derived: sum of 3 quarters · filed 2026-03-05 | $200.70M derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $46.46M 10-Q · filed 2025-05-14 | $93.90M derived: sum of 2 quarters · filed 2026-03-05 | $143.69M derived: sum of 3 quarters · filed 2026-03-05 | $188.25M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $47.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $97.23M derived: sum of 2 quarters · filed 2026-03-05 | $141.79M derived: sum of 3 quarters · filed 2026-03-05 | $172.95M 10-K · filed 2026-03-05 |
| 2023-09-30 | $49.79M 10-Q · filed 2024-11-13 | $94.35M derived: sum of 2 quarters · filed 2024-11-13 | $125.52M 10-Q · filed 2024-11-13 | $155.82M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $44.56M 10-Q · filed 2024-08-02 | $75.72M 10-Q · filed 2024-08-02 | $106.03M derived: sum of 3 quarters · filed 2025-03-07 | $129.16M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $31.17M 10-Q · filed 2024-05-02 | $61.47M derived: sum of 2 quarters · filed 2025-03-07 | $84.61M derived: sum of 3 quarters · filed 2025-03-07 | $108.65M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $30.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $53.44M derived: sum of 2 quarters · filed 2025-03-07 | $77.48M derived: sum of 3 quarters · filed 2025-03-07 | $100.90M 10-K · filed 2025-03-07 |
| 2022-09-30 | $23.13M 10-Q · filed 2023-11-08 | $47.18M derived: sum of 2 quarters · filed 2023-11-08 | $70.59M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $24.04M 10-Q · filed 2023-08-04 | $47.46M 10-Q · filed 2023-08-04 | ||
| 2021-12-31 | $87.39M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |